1. Home
  2. ARBEW vs ERNAW Comparison

ARBEW vs ERNAW Comparison

Compare ARBEW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd. Warrant

ARBEW

Arbe Robotics Ltd. Warrant

N/A

Current Price

$0.05

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Logo Ernexa Therapeutics Inc. Warrants

ERNAW

Ernexa Therapeutics Inc. Warrants

N/A

Current Price

$0.03

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARBEW
ERNAW
Founded
2015
N/A
Country
Israel
United States
Employees
145
5
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARBEW
ERNAW
Price
$0.05
$0.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.4K
3.1K
Earning Date
03-05-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$768,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.02
52 Week High
$0.50
$0.11

Technical Indicators

Market Signals
Indicator
ARBEW
ERNAW
Relative Strength Index (RSI) 44.80 42.99
Support Level $0.04 $0.02
Resistance Level $0.08 $0.06
Average True Range (ATR) 0.01 0.01
MACD 0.00 0.00
Stochastic Oscillator 23.75 4.87

Price Performance

Historical Comparison
ARBEW
ERNAW

About ARBEW Arbe Robotics Ltd. Warrant

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles, as well as for non-automotive uses. Geographically, the company generates maximum revenue from Sweden, and the rest from China, Hong Kong, the USA, Germany, Israel, and other markets.

About ERNAW Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: